Natriumjodid (I-131) Curiumpharma (Sodium Iodide (131i))

Sodium Iodide I-131 is taken up by thyroid cells through the sodium‑iodide symporter. Inside the gland, the I-131 isotope emits beta radiation that damages cellular DNA, causing selective destruction of thyroid tissue while minimizing exposure to surrounding organs.

The prescribed dose of Natriumjodid (I-131) is individualized by the treating physician based on factors such as the specific indication, thyroid gland size, iodine uptake studies, patient weight, and overall clinical condition. No standard dosing can be provided without a medical assessment.

Use of radioactive iodine is generally contraindicated in pregnancy because the fetus’s thyroid can be damaged. Breastfeeding should be discontinued during treatment and for a period recommended by the physician, as the drug can be secreted in milk and affect the infant’s thyroid.

To order Natriumjodid (I-131), submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Non‑radioactive iodine supplements provide dietary iodine but do not deliver therapeutic radiation. Natriumjodid (I-131) combines iodine uptake with beta radiation, allowing selective destruction of thyroid tissue, which is essential for conditions like hyperthyroidism and post‑surgical thyroid cancer ablation where simple supplementation is ineffective.

Store Natriumjodid (I-131) at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture, light, and physical damage, and ensure that it is stored out of reach of unauthorized personnel.

Natriumjodid (I-131) is administered orally, typically as a single dose in liquid or capsule form, under the supervision of a qualified healthcare professional. The patient may be instructed to fast before and after dosing to optimize thyroid uptake of the radioactive iodine.

Serious risks include severe hypothyroidism requiring lifelong hormone replacement, radiation‑induced thyroiditis, bone marrow suppression leading to cytopenias, and rare allergic reactions such as anaphylaxis. Long‑term monitoring of thyroid function and blood counts is essential after therapy.

Patients with known hypersensitivity to iodine or radioactive iodine, pregnant women, nursing mothers (unless the benefit outweighs risk), and individuals with uncontrolled severe cardiac disease or active infection should generally avoid Natriumjodid (I-131). Final eligibility must be determined by the prescribing physician.